• Explore /
  • Poster
  • / Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline TP53m AML patients: Phase 1b results.

Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline TP53m AML patients: Phase 1b results.

Abstract Poster

Authors

null

Naval Guastad Daver

Department of Leukemia, MD Anderson Cancer Center, Houston, TX

Naval Guastad Daver , Paresh Vyas , Suman Kambhampati , Monzr M. Al Malki , Richard A. Larson , Adam Steven Asch , Gabriel N. Mannis , Wanxing Chai-Ho , Tiffany N. Tanaka , Terrence J. Bradley , Deepa Jeyakumar , Eunice S. Wang , Guan Xing , Mark Chao , Giridharan Ramsingh , Camille Renard , Indu Lal , Joshua F. Zeidner , David Andrew Sallman

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies

Sub Track

Acute Leukemia

Clinical Trial Registration Number

NCT03248479

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 7020)

DOI

10.1200/JCO.2022.40.16_suppl.7020

Abstract #

7020

Poster Bd #

251

Abstract Disclosures

Similar Posters

First Author: James Yuhtyng Chen

First Author: David Andrew Sallman

First Author: Jian Zhou

First Author: A. Dimitrios Dimitrios Colevas